Quest PharmaTech (CVE:QPT) Stock Price Down 25% – Should You Sell?

Quest PharmaTech Inc. (CVE:QPT) dropped 25% during mid-day trading on Wednesday . The stock traded as low as C$0.03 and last traded at C$0.03. Approximately 123,238 shares changed hands during trading, an increase of 414% from the average daily volume of 23,982 shares. The stock had previously closed at C$0.04.

Quest PharmaTech Price Performance

The firm has a market capitalization of C$5.07 million, a P/E ratio of -30.00 and a beta of 0.00. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The business’s 50 day moving average is C$0.04 and its 200-day moving average is C$0.04.

Quest PharmaTech Company Profile

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.